GlassScriptPhysician profile
Diana Trusky
NPI 1245238294
$1,254.15
in general payments reported to CMS, 2019-2025
13 companies · $40.16 in 2025
The $40.16 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $60.28 · 2021: $147 · 2022: $335 · 2023: $220 · 2025: $40.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $165 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $165.35 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $451.37 | 2019 | |
| Epi Health, LLC | $215.72 | 2020-2022 | |
| Dermavant Sciences, INC. | $139.19 | 2022-2023 | Vtama |
| Genzyme Corporation | $128.48 | 2021-2022 | |
| Journey Medical Corporation | $106.55 | 2022 | |
| Janssen Biotech, INC. | $94.99 | 2023 | Tremfya |
| Allergan, INC. | $36.10 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $18.57 | 2025 | Libtayo |
| Krystal Biotech INC | $16.19 | 2025 | Vyjuvek |
| Helsinn Therapeutics (U.S.), INC. | $14.25 | 2020 | |
| Almirall LLC | $13.98 | 2021 | |
| Lilly USA, LLC | $13.36 | 2022 | |
| Organon LLC | $5.40 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Trusky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.